Clinical Characteristics and Outcomes of Diabetic COVID-19 patients in Kuwait

Hamad Ali^{1,2*}, Abdullah Alshukry³, Mohammad Bu Abbas³, Yaseen Ali³, Barrak Alahmad⁴, Abdullah A. Al-Shammari^{2,5}, Mohammad Abu-Farha², Jehad AbuBaker², Sriraman Devarajan², Ali A. Dashti¹ and Fahd Al-Mulla²

- 1. Department of Medical Laboratory Sciences, Faculty of Allied Health Sciences, Health Sciences Center (HSC), Kuwait University, Kuwait
- 2. Dasman Diabetes Institute (DDI), Dasman, Kuwait
- 3. Department of Otolaryngology & Head and Neck Surgery, Jaber Al-Ahmad Hospital, Ministry of Health, Kuwait
- 4. Department of Environmental Health, Harvard T.H. Chan School of Public Health, Harvard University, Boston, MA, USA.
- 5. Department of Mathematics, Faculty of Sciences, Kuwait University, Kuwait

^{*}Corresponding author: Hamad.ali@ku.edu.kw

Abstract

Background: Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) emerged in

Wuhan, China, in 2019 and rapidly turned into a global pandemic, resulting in what is now

known as Coronavirus Disease 2019 (COVID-19). COVID-19 has a highly variable clinical

presentation, ranging from asymptomatic to severe respiratory symptoms and death. Diabetes

seems to be one of the main comorbidities contributing to a worse COVID-19 outcome.

Methods: In this single-center, retrospective study of 417 consecutive COVID-19 patients in

Kuwait, we analyze and compare disease severity, outcome, associated complications, and

clinical laboratory findings between diabetic and non-diabetic COVID-19 patients. Results:

COVID-19 patients with diabetes had a higher prevalence of comorbidities, such as

hypertension, higher levels of inflammatory markers, lower estimated glomerular filtration

rate, and a higher incidence of complications. All of these factors could lead to more severe

outcomes and higher mortality than non-diabetic COVID-19 patients. Conclusion: Diabetes

could be a major contributor to COVID-19 worsening outcomes.

Keywords: COVID-19, Diabetes Mellitus, SARS-CoV2, inflammation, CRP

1. Introduction

In December 2019, a novel coronavirus, now known as Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), emerged in Wuhan, China[1]. Since then, it has spread rapidly all over the world and was declared a pandemic by the World Health Organization on March 11, 2020. With the number of cases currently reaching 22 million and more than 800,000 deaths, the virus poses a major threat to global health[2, 3].

Coronavirus Disease 2019 (COVID-19), the disease caused by the virus, has shown a highly variable clinical presentation, ranging from asymptomatic to severe illness leading to death. The symptoms of COVID-19 include fever, cough, dyspnea, myalgia, fatigue, headache, and loss of taste or smell. Most patients experience mild symptoms, although some may develop serious complications, including acute respiratory distress syndrome (ARDS), multiorgan failure, septic shock, and hypercoagulation, which can eventually lead to death[4-8]. The exact reasons for the observed variability in disease manifestations and outcomes are not fully understood. Whereas pediatric cases show a milder clinical course[9], a worse prognosis has been associated with older age and being male[8]. Emerging evidence also indicates that preexisting medical conditions, including hypertension, cardiovascular disease, chronic kidney disease, chronic obstructive pulmonary disease, solid organ transplantation, and diabetes, can increase the risk of poor COVID-19 prognosis[10-13].

Diabetes mellitus is a chronic metabolic disease characterized by the occurrence of hyperglycemia for a prolonged period. It is associated with serious long-term complications, including cardiovascular disease and chronic kidney disease [14]. Diabetes, which affects 463

million people, has a major impact on global health. It is among the top 10 causes of adult deaths worldwide[15]. In the past two decades, two coronaviruses have emerged that have caused widespread respiratory illness and deaths. In 2002, SARS coronavirus (SARS-CoV) emerged in China, causing severe acute respiratory syndrome coronavirus. In 2012, another coronavirus, MERS-coronavirus (MERS-CoV), emerged in Saudi Arabia, causing Middle East respiratory syndrome. Experience with both syndromes revealed that diabetes was a risk factor for poor prognosis and mortality[16, 17]. Similarly, initial reports of the clinical characteristics of COVID-19 showed a similar trend[1, 8, 18]. Given the global burden of diabetes and the pandemic course of SARS-CoV-2, understanding how diabetes contributes to a worse COVID-19 prognosis is important. Several studies have shown that type 2 diabetes, which is the most prevalent type of the disease, is associated with low-grade chronic inflammation that affects the homeostatic glucose regulation and insulin sensitivity. The combination of chronic inflammation and hyperglycemia could contribute to an abnormal immune response by weakening T-cell function, in addition to an increased risk of hyperinflammation and cytokine storm syndrome[19, 20], which in turn can worsen the COVID-19 disease outcome.

Understanding how diabetes worsens COVID-19 outcomes can help provide better disease management and contribute to the improvement in disease outcomes. In this study, we perform a comprehensive clinical analysis of COVID-19 patients with and without type 2 diabetes. We analyze and compare the distribution of disease severity, associated complications, and death outcomes between the two groups.

2. Subjects and Methods

2.1 Study design

The Standing Committee for Coordination of Health and Medical Research at the Ministry of Health in Kuwait reviewed and approved this retrospective study (Institutional Review Board 2020/1404). The Standing Committee waived the requirement for written informed consent because of the urgency of data collection and the exceptional nature of the disease. All procedures involving human participants were performed following the relevant guidelines and regulations. The medical records of confirmed COVID-19 cases admitted to Jaber Al-Ahmad Hospital in Kuwait between February 24 and May 24, 2020, were accessed, analyzed, and included in this study. The diagnosis of COVID-19 was established based on positive viral realtime reverse transcriptase-polymerase chain reaction (RT-PCR) assay of nasal and/or pharyngeal swabs, following the World Health Organization's interim guidance. Cases were divided into two main groups: patients with diabetes and patients without diabetes. The diagnosis of diabetes was based on a fasting plasma glucose value of ≥7.0 mmol/L [21]. Only type 2 diabetes patients were considered in this study as no type 1 diabetes patients were encoutnered. Laboratry diagnosis was confirmed with medical history. Each group was further divided into the following subgroups depending on COVID-19 severity and outcome: asymptomatic, symptomatic with mild/moderate symptoms, intensive care unit (ICU) survivors, and ICU death. Data presented in this study was made available on springer nature data depository[22] and can be accessed via https://doi.org/10.6084/m9.figshare.12567881.v1.

2.2 Data collection

We included 417 confirmed COVID-19 patients in the study. The patients' medical records were accessed and analyzed by our team at Dasman Diabetes Institute, Faculty of Allied Health Sciences at Kuwait University, and Jaber Al-Ahmad Hospital. We obtained and analyzed demographic data, medical history, including underlying comorbidities, travel history, contact tracing data, clinical chemistry, hematological laboratory findings, chest radiological images, treatments, complications, ICU admissions and durations, and dynamics of hospital stay and outcomes. The diagnosis of ARDS was determined based on the Berlin definition[23]. Acute kidney injury was evaluated following the Kidney Disease: Improving Global Outcomes definition[24]. The presence of cardiac injury was established based on cardiac blood markers, electrocardiography, and/or echocardiography[7].

2.3 Hospitalization dynamics

During the patient recruitment period, Jaber Al-Ahmad Hospital by the Ministry of Health instituted a 100% hospitalization policy for COVID-19—positive cases. All cases with a positive RT-PCR test, including asymptomatic cases, were admitted, isolated, and put under medical surveillance. Patients in the mild/moderate group, who were hemodynamically stable and had no signs of respiratory distress, were admitted to the ward after RT-PCR confirmation for isolation, medical surveillance, and reevaluation. Patients were transferred to the ICU if they developed signs of respiratory distress and desaturation of oxygen levels (confirmed by pulse oximetry and arterial blood gases) and/or signs of hemodynamic instability that required close

monitoring and intensive re-establishment of homeostasis. Patients with severe to critical COVID-19 symptoms were admitted directly to the ICU if they matched any of the following criteria of severity: hypoxemic respiratory failure requiring respiratory support, such as patients who developed ARDS; hemodynamic instability due to cardiogenic or septic shock and clinical, radiological, or laboratory evidence of heart failure; acute cardiac injury; and acute kidney injury secondary to COVID-19 manifestations.

2.4 Statistical analysis

The variables analyzed in the study were divided into categorical and continuous variables. The categorical variables were described as frequencies and percentages, whereas continuous variables were presented as medians and interquartile ranges and means and standard deviations. We used a one-way analysis of variance to compare means between groups; we used the Kruskal–Wallis H test to compare the medians of the different group laboratory parameters. Categorical variables were analyzed using the chi-square test, and when the data were limited, Fisher exact test was used. The differences between group means and medians were considered statistically significant when p < 0.05. We investigated the relationship between fasting blood glucose as a continuous exposure and ICU admission as an outcome from COVID-19 as a binary response and adjusted to other covariates (age, gender, smoking status, diabetes status, and other comorbidities). We employed a logistic regression model and reported the odds ratios of the outcome of dying from COVID-19 for each 1 mmol/L increase in fasting blood glucose. All statistical analyses were performed using GraphPad Prism software (La Jolla, CA, USA), SPSS (Statistical Package for Social Sciences) for Windows version 25.0 (IBM)

SPSS Inc., Chicago, IL, USA) and R version 3.4.3 (R Foundation for Statistical Computing, Vienna, Austria).

3. Results

3.1 Cohort characteristics

The studied cohort consisted of 417 COVID-19 patients who were divided into two groups based on fasting blood glucose levels: 273 (65.5%) non-diabetic patients and 122 (29.3%) diabetic patients (Table 1). The mean age of the non-diabetic group was 39.55 (\pm 16.59) years, whereas the mean age of the diabetic group was 56.44 (\pm 11.64) years (p < 0.001, Student t-test; Table 1 and supplementry Figure 1). The diabetic group had a greater incidence of fever, shortness of breath, and fatigue than the non-diabetic group (p < 0.05, < 0.001, and < 0.05, respectively). However, the differences in other symptoms were not significant between the two groups (Table 1).

The diabetic group had a higher prevalence of comorbidities including hypertension, asthma, cardiovascular disease, and chronic renal disease (p < 0.001, < 0.05, < 0.001, and < 0.005, respectively; Table 1).

3.2 COVID-19 severity, outcome, and associated complications

In terms of COVID-19 severity, we found no statistically significant difference in the percentages of asymptomatic and mild-moderate cases between the diabetic and non-diabetic groups (Table 2). However, the diabetic group included a significantly higher proportion of patients requiring admission to the ICU (p < 0.001). Without adjustment, the diabetes group had a

significantly higher percentage of death as compared with the non-diabetic group (16.7% vs. 12.1%, p < 0.001; Table 2). The diabetic group also had a significantly higher prevalence of complications, including sepsis, ARDS, cardiovascular disease, heart failure, and kidney injury when compared with the non-diabetic group (p < 0.001; Table 2).

3.3 Fasting blood glucose level and odds ratio of death

We used a logistic regression model and reported the odds ratios of the outcome of dying from COVID-19 for each 1-mmol/L increase in fasting blood glucose. We found that every 1 mmol/L increase in fasting glucose is associated with 1.52 (95% CI: 1.34 - 1.72, p<0.001) times the odds of dying from COVID-19.

3.4 Clinical biochemistry findings

The diabetic and non-diabetic groups were subdivided into asymptomatic, mild-moderate, and severe categories. The clinical biochemistry findings were compared between the patients with and without diabetes in the subcategories of COVID-19 severity (Table 3). The cohort was categorized and divided according to the fasting blood glucose level. We noted a significant difference in fasting blood glucose between the diabetic and non-diabetic groups across all subcategories. The mean estimated glomerular filtration rate (eGFR) was significantly lower in the diabetic group than the non-diabetic group in all subcategories. The lowest value was in the severe group (57.50 \pm 33.81 vs. 76.46 \pm 34.14 mL/min/1.73 m², p < 0.05). The other renal markers, creatinine and urea, were higher in general in the diabetic groups than the non-diabetic groups. However, the results were significant only in the severe subcategory (p < 0.05 for both markers). The C-reactive protein levels were significantly higher among diabetic

patients than non-diabetic patients in all subcategories (p < 0.05, < 0.05, and < 0.005, in order; Table 3). Although procalcitonin levels were higher in all diabetic groups, the difference was not statistically significant. The albumin level was significantly lower in the diabetic groups across all subcategories than the non-diabetic groups (p < 0.001, < 0.001, and < 0.05, in order). White blood cell counts and neutrophil counts were significantly higher in the diabetic group in the severe subcategory as compared with the non-diabetic group (p < 0.05 and < 0.005, respectively; Table 3).

4. Discussion

COVID-19 has displayed a broad spectrum of severity, ranging from asymptomatic to severe illness leading to death. Many factors have influence disease outcome, including age and gender. Severe outcomes have been associated with preexisting chronic illnesses, such as hypertension and diabetes. In this study, we presented the clinical characteristics and outcomes of diabetic COVID-19 patients in Kuwait.

In general, we found that patients with diabetes had more severe COVID-19 outcomes than patients without diabetes, represented by the higher proportion of ICU admitted cases (severe) and deaths (Table 2). Our results are in agreement with the findings obtained from a Chinese COVID-19 cohort, in which COVID-19 diabetic patients had a 7.3% increased risk of mortality compared with 2.3% for the general population[25]. Moreover, a British cohort showed that COVID-19 patients with uncontrolled diabetes had a higher risk of death than other patients did[26]. The reason why individuals with diabetes are likely to have a worse COVID-19 prognosis seems to be multifactorial because of the syndromic nature of diabetes. In our

cohort, we found that diabetic patients were older, had a higher prevalence of comorbidities, such as hypertension, had higher levels of inflammatory markers, had a lower eGFR, and had a higher prevalence of complications, all of which lead to worse COVID-19 outcomes (Figure 1; Tables 1–3). Such findings indicate the possible multifaceted pathological mechanistic pathways that lead to worse outcomes in COVID-19 diabetic patients.

Inflammation plays a critical role in diabetes pathogenesis, whereby diabetic patients typically develop a chronic state of inflammation[27]. We found significantly higher levels of C-reactive protein in all of our COVID-19 diabetic patients than non-diabetic COVID-19 patients (Table 3). This finding could be associated with an inflammatory status that makes these patients more susceptible to the damaging effects of what is known as the COVID-19 cytokine storm, which leads to multiorgan failure and death[28].

The higher prevalence of comorbidities in diabetic patients can also contribute to their poor COVID-19 outcomes. Among the diabetic patients in this study, we noted a higher prevalence of hypertension and cardiovascular disease (57.6% and 14.1%, respectively) compared with the non-diabetic patients (14.7% and 4.4,% respectively; Table 1). Such results agree with the findings reported in a study conducted in Wuhan, China (56.9% and 20.9%, respectively)[29]. We also noted a significantly lower eGFR upon admission for diabetic patients as compared with non-diabetic individuals (Table 3). This finding coincided with a higher incidence of acute kidney injury among diabetic patients than non-diabetic patients (24.3% and 2.2%, respectively, p < 0.001; Table 2). Diabetic patients have a higher risk of developing chronic kidney disease, which can eventually lead to kidney failure. The situation is worse in diabetic COVID-19

patients, because SARS-CoV-2 is likely to target the kidney through an angiotensin-converting enzyme 2—dependent pathway, leading to renal impairment and death[30].

Our logistic regression model showed a positive correlation between fasting blood glucose levels and increased risk of COVID-19 death, with adjustment for other risk factors including age, gender, smoking status, and other comorbidities. This finding might suggest that elevated glucose levels could be the primary molecular trigger for a cascade of pathological events that contribute to the poor outcome associated with COVID-19 in diabetic patients.

5. Conclusion

In conclusion, diabetes is one of the major risk factors associated with the poor outcome and mortality of COVID-19 patients. COVID-19 patients with diabetes have a higher prevalence of comorbidities such as hypertension, higher levels of inflammatory markers, lower eGFR, and a higher incidence of in-hospital complications, which illustrates the possible multifaceted pathological mechanistic pathways triggered by hyperglycemia that lead to worse outcomes and mortality.

Authors contributions

HA was involved in the conception and design of the study, data analysis and interpretation,

drafting the article and took the final approval of the version submitted. AA1 was involved in

acquisition of data. MB was involved in acquisition of data. YA was involved in acquisition of

data. BA was involved in data analysis. AA2, was involved in data analysis. MA was involved in

revision of article for important intellectual conent. JA was involved in revision of article for

important intellectual conent. SD was involved in data analysis. AD wa involved in data

interpretation. FA was involved in critical revision of article for important intellectual conent

and data interpretation. All authors have approved the final version of article.

Acknowledgments

We would like to thank the adminstation of Jaber Al-Ahmad hospital for facilitating and

supporting this work.

Conflict of interest

The authors have no conflicts of interest to declare. All co-authors have seen and agree with

the contents of the manuscript and there is no financial interest to report.

Funding

No funding was obtained for the presented work.

Table 1. Cohort characteristics stratified by diabetic status

	Non-Diabetics	Diabetics	P-value					
Gender								
Males	169 (61.9)	93(64.6)	0.59					
Females	104 (38.1)	51 (35.4)	0.59					
total	273 (65.5)	144 (34.5)						
Age (years)	39.55 (± 16.59)	56.44 (± 11.64)	<0.001					
Symptoms								
Fever	83(30.4)	60(41.7)	0.022					
Chills	5(1.8)	6(4.2)	0.166					
Dysgeusia	1(0.4)	0(0)	0.359					
Dry Cough	83(30.4)	53(36.8)	0.187					
Productive Cough	13(4.8)	13(9.1)	0.091					
Headache	22(8.1)	5(3.5)	0.06					
Chest Pain	4(1.5)	6(4.2)	0.095					
Syncope	0(0)	1(0.7)	0.143					
Runny Nose	12(4.4)	2(1.4)	0.082					
Sore Throat	44(16.1)	17(11.8)	0.229					
Shortness of Breadth	20(7.3)	56(38.9)	<0.001					
Nausea	7(2.6)	5(3.5)	0.603					
Vomiting	5(1.8)	5(3.5)	0.31					
Abdominal Pain	3(1.1)	9(6.3)	0.004					
Diarrhea	8(2.9)	5(3.5)	0.764					
Fatigue	20(7.3)	20(13.9)	0.034					
Myalgia	33(12.1)	15(10.4)	0.609					
Comorbidities								
Hypertension	40 (14.7)	83 (57.6)	<0.001					
Asthma	21 (7.7)	20 (14.1)	0.044					
COPD	1 (0.4)	0 (0)	0.359					
Cardiovascular disease	12 (4.4)	27 (18.8)	<0.001					
Chronic renal disease	4 (1.5)	10 (6.9)	0.004					
Malignancy	8 (2.9)	4 (2.8)	0.924					

Table 2. COVID-19 severity, outcome and associated complications among diabetics and non-diabetics

	Non-Diabetics	Diabetics	P-value					
Disease Category*								
Asymptomatic	119 (43.6)	45 (31.3)						
Mild/Moderate	133 (48.7)	38 (26.4)						
Severe	46 (16.8)	29 (20.1)	<0.001					
Death cases	th cases 33 (12.1)		<0.001					
In-hospital complications								
Sepsis	13 (4.8)	44 (31)	<0.001					
ARDS	18 (6.6)	61 (42.4)	<0.001					
Heart Failure	9 (3.3)	43 (30.5)	<0.001					
Cardiac Injury	liac Injury 7 (2.6)		<0.001					
Kidney Injury 6 (2.2)		35 (24.3)	<0.001					

Table 3. Clinical biochemistry findings per group stratified by diabetic status

	ASYMPTOMATIC (N=164)			MILD-MODERATE GROUP (N=171)		SEVERE SYMPTOMS (N=82)			
	Non- Diabetics (N=119)	Diabetics (N=45)		Non- Diabetics (N=133)	Diabetics (N=38)		Non- Diabetics (N=37)	Diabetics (N=45)	
VARIABLES	Mean ±SD	Mean ±SD	p-value	Mean ±SD	Mean ±SD	p- value	Mean ±SD	Mean ±SD	p-value
eGFR mL/min/1.73m ²	109.64 ±19.27	95.10 ±17.2	<0.001	104.97 ±18.61	91.71 ±23.59	.002	76.46 ±34.14	57.50 ±33.81	.035
CRP mg/L	6.22 ±8.81	13.61 ±21.91	.033	22.34 ±30.66	38.89 ±35.91	.016	110.75 ±90.61	195.12 ±109.55	.003
PCT ng/ml	0.04 ±0.02	0.06 ±0.1	.258	0.10 ±0.12	0.12 ±0.14	.721	5.72 ±11.23	10.13 ±21.32	.233
Glucose mmol/L	5.25 ±0.61	7.47 ±2.62	<0.001	5.44 ±0.6	8.59 ±2.47	<0.001	5.73 ±0.59	11.11 ±3.52	<0.001
Urea mmol/L	3.47 ±0.99	3.87 ±1.49	.101	4.61 ±11.39	4.86 ±3.27	.823	10.41 ±8.19	14.79 ±9.03	.047
Creatinine mmol/L	63.73 ±16.86	65.03 ±16.85	.660	73.25 ±50.78	81.49 ±58.51	.435	145.84 ±110.02	212.98 ±181.77	.049
Albumin g/L	38.30 ±3.11	35.49 ±3.95	<0.001	36.02 ±4.36	32.89 ±4.62	<0.001	24.92 ±5.35	21.91 ±4.53	.028
ALP IU/L	74.85 ±45.36	67.09 ±31.03	.214	61.87 ±26.9	68.99 ±22.97	.110	88.46 ±34.61	102.11 ±56.52	.197
WBC x10^9 /L	6.61 ±1.92	6.15 ±1.87	.163	6.47 ±1.9	6.99 ±4.69	.502	9.95 ±4.28	12.70 ±5.62	.024
Platelet x10^9 /L	270.40 ±63.14	287.16 ±113.57	.353	278.40 ±76.63	314.24 ±121.47	.092	278.35 ±126.84	274.61 ±88.67	.901
RBC x10^12 /L	5.02 ±0.65	5.05 ±0.61	.792	5.11 ±1.68	4.87 ±0.66	.180	5.63 ±7.57	4.00 ±0.63	.335
HB g/L	137.00 ±35.91	131.63 ±18.09	.209	135.27 ±16.17	126.63 ±16.82	.007	108.47 ±24.73	108.21 ±17.57	.964
D-Dimer mg/L	277.38 ±142.08	164.67 ±57.12	.095	393.21 ±260.43	368.10 ±251.16	.802	2329.35 ±2140.98	3332.37 ±3995.75	.256
Neutrophils x10^9 /L	3.20 ±1.15	3.00 ±1.42	.390	3.48 ±1.32	3.54 ±0.99	.768	7.46 ±3.71	10.86 ±5.50	.003
Lymphocytes x10^9 /L	2.58 ±1.42	2.37 ±0.66	.196	2.15 ±0.65	2.69 ±4.41	.460	1.20 ±.57	1.03 ±0.45	.219
Monocytes x10^9 /L	0.59 ±0.15	0.57 ±0.16	.478	0.59 ±0.19	0.59 ±0.24	.911	0.63 ±.0.36	0.64 ±0.42	.882
Eosinophils x10^9 /L	0.19 ±0.16	0.17 ±0.17	.588	0.15 ±12	0.15 ±0.13	.809	0.21 ±0.51	0.13 ±0.3	.476
Basophils %	0.01 ±0.02	0.01 ±0.02	.667	0.01 ±0.02	0.01 ±0.03	.847	0.02 ±0.02	0.02 ±0.03	.992

6. References

- [1] Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497-506.
- [2] Dong E, Du H, Gardner L. An interactive web-based dashboard to track COVID-19 in real time. Lancet Infect Dis. 2020.
- [3] Al-Shammari AAA, Ali H, Al-Ahmad B, Al-Refaei FH, Al-Sabah S, Jamal MH, et al. Real-time tracking and forecasting of the COVID-19 outbreak in Kuwait: a mathematical modeling study. medRxiv. 2020:2020.05.03.20089771.
- [4] Bai Y, Yao L, Wei T, Tian F, Jin DY, Chen L, et al. Presumed Asymptomatic Carrier Transmission of COVID-19. JAMA. 2020.
- [5] Lai CC, Liu YH, Wang CY, Wang YH, Hsueh SC, Yen MY, et al. Asymptomatic carrier state, acute respiratory disease, and pneumonia due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): Facts and myths. J Microbiol Immunol Infect. 2020.
- [6] Wu F, Zhao S, Yu B, Chen YM, Wang W, Song ZG, et al. A new coronavirus associated with human respiratory disease in China. Nature. 2020;579:265-9.
- [7] Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 2020.
- [8] Alshukry A, Ali H, Ali Y, Al-Taweel T, Abu-farha M, AbuBaker J, et al. Clinical characteristics of Coronavirus Disease 2019 (COVID-19) patients in Kuwait. medRxiv. 2020:2020.06.14.20131045.
- [9] Lu X, Zhang L, Du H, Zhang J, Li YY, Qu J, et al. SARS-CoV-2 Infection in Children. N Engl J Med. 2020;382:1663-5.
- [10] Williamson E, Walker AJ, Bhaskaran KJ, Bacon S, Bates C, Morton CE, et al. OpenSAFELY: factors associated with COVID-19-related hospital death in the linked electronic health records of 17 million adult NHS patients. medRxiv. 2020:2020.05.06.20092999.
- [11] Guo T, Fan Y, Chen M, Wu X, Zhang L, He T, et al. Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19). JAMA Cardiol. 2020.
- [12] Yang J, Zheng Y, Gou X, Pu K, Chen Z, Guo Q, et al. Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis. Int J Infect Dis. 2020;94:91-5.
- [13] Zheng Z, Peng F, Xu B, Zhao J, Liu H, Peng J, et al. Risk factors of critical & mortal COVID-19 cases: A systematic literature review and meta-analysis. J Infect. 2020.
- [14] Forbes JM, Cooper ME. Mechanisms of diabetic complications. Physiol Rev. 2013;93:137-88.
- [15] Saeedi P, Petersohn I, Salpea P, Malanda B, Karuranga S, Unwin N, et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9(th) edition. Diabetes Res Clin Pract. 2019;157:107843.
- [16] Badawi A, Ryoo SG. Prevalence of comorbidities in the Middle East respiratory syndrome coronavirus (MERS-CoV): a systematic review and meta-analysis. Int J Infect Dis. 2016;49:129-33.
- [17] Yang JK, Feng Y, Yuan MY, Yuan SY, Fu HJ, Wu BY, et al. Plasma glucose levels and diabetes are independent predictors for mortality and morbidity in patients with SARS. Diabet Med. 2006;23:623-8.
- [18] Petrosillo N, Viceconte G, Ergonul O, Ippolito G, Petersen E. COVID-19, SARS and MERS: are they closely related? Clin Microbiol Infect. 2020;26:729-34.
- [19] lacobellis G. COVID-19 and diabetes: Can DPP4 inhibition play a role? Diabetes Res Clin Pract. 2020;162:108125.
- [20] de Lucena TMC, da Silva Santos AF, de Lima BR, de Albuquerque Borborema ME, de Azevedo Silva J. Mechanism of inflammatory response in associated comorbidities in COVID-19. Diabetes Metab Syndr. 2020;14:597-600.

- [21] American Diabetes A. 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2020. Diabetes Care. 2020;43:S14-S31.
- [22] Abdullah A, Hamad A, Yaseen A, Talal Al T, Mohammad A-F, Jehad Abu B, et al. Data underlying the manuscript: Clinical characteristics of Coronavirus Disease 2019 (COVID-19) patients in Kuwait2020.
- [23] Force ADT, Ranieri VM, Rubenfeld GD, Thompson BT, Ferguson ND, Caldwell E, et al. Acute respiratory distress syndrome: the Berlin Definition. JAMA. 2012;307:2526-33.
- [24] Levey AS, Eckardt KU, Tsukamoto Y, Levin A, Coresh J, Rossert J, et al. Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2005;67:2089-100.
- [25] Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases From the Chinese Center for Disease Control and Prevention. JAMA. 2020.
- [26] Williamson EJ, Walker AJ, Bhaskaran K, Bacon S, Bates C, Morton CE, et al. OpenSAFELY: factors associated with COVID-19 death in 17 million patients. Nature. 2020.
- [27] Donath MY, Shoelson SE. Type 2 diabetes as an inflammatory disease. Nat Rev Immunol. 2011;11:98-107.
- [28] Mancia G, Rea F, Ludergnani M, Apolone G, Corrao G. Renin-Angiotensin-Aldosterone System Blockers and the Risk of Covid-19. N Engl J Med. 2020;382:2431-40.
- [29] Shi Q, Zhang X, Jiang F, Zhang X, Hu N, Bimu C, et al. Clinical Characteristics and Risk Factors for Mortality of COVID-19 Patients With Diabetes in Wuhan, China: A Two-Center, Retrospective Study. Diabetes Care. 2020;43:1382-91.
- [30] Zhang YM, Zhang H. Genetic Roadmap for Kidney Involvement of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection. Clin J Am Soc Nephrol. 2020;15:1044-6.

Supplemantary




Figure 1. Cohort age structure stratified by diabetes status. On average, non-diabetic group had a mean age of 39.55 (\pm 16.59) years while diabetic group had a mean age of 56.44 (\pm 11.64) years (p-value <0.001, student's T test).